DrugPatentWatch Database Preview
VIEKIRA PAK (COPACKAGED) Drug Profile
or, see our see our flat-rate plans
When do Viekira Pak (copackaged) patents expire, and what generic alternatives are available?
This drug has five hundred and twenty-five patent family members in fifty-one countries.
The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir profile page.
Summary for VIEKIRA PAK (COPACKAGED)
| International Patents: | 525 |
| US Patents: | 18 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 4 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIEKIRA PAK (COPACKAGED) |
| DailyMed Link: | VIEKIRA PAK (COPACKAGED) at DailyMed |
US Patents and Regulatory Information for VIEKIRA PAK (COPACKAGED)
or, see our see our flat-rate plans
Expired US Patents for VIEKIRA PAK (COPACKAGED)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for VIEKIRA PAK (COPACKAGED)
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,716,454 | Solid compositions | ➤ Try a Free Trial |
| 8,809,265 | Methods for treating HCV | ➤ Try a Free Trial |
| 8,025,899 | Solid pharmaceutical dosage form | ➤ Try a Free Trial |
| 7,659,405 | Polymorph of a pharmaceutical | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
or, see our see our flat-rate plans
International Patents for VIEKIRA PAK (COPACKAGED)
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2203431 | ➤ Try a Free Trial |
| South Korea | 20150008151 | ➤ Try a Free Trial |
| Canada | 2837129 | ➤ Try a Free Trial |
| Hong Kong | 1186415 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for VIEKIRA PAK (COPACKAGED)
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0150016 00154 | Estonia | ➤ Try a Free Trial | PRODUCT NAME: OMBITASVIIR;REG NO/DATE: EU/1/14/982 19.01.2015 |
| 2015000039 | Germany | ➤ Try a Free Trial | PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| 2015 00014 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 |
| 668 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
